7
Clinical Trials associated with JY-231 / Not yet recruitingNot ApplicableIIT An Early Exploratory Clinical Study of the Safety, Tolerability and Preliminary Efficacy of JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma/Leukaemia
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory B cell lymphoma / leukemia. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed or refractory B cell lymphoma / leukemia.
JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE) - A Safety, Tolerability, and Efficacy Study
Early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of active systemic lupus erythematosus (SLE)
/ RecruitingEarly Phase 1IIT JY231 Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia(B-ALL ) Early Exploratory Clinical Studies on Safety, Tolerability, and Initial Efficacy
Early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of B-cell acute lymphoblastic leukemia( B-ALL )
100 Clinical Results associated with JY-231
100 Translational Medicine associated with JY-231
100 Patents (Medical) associated with JY-231
100 Deals associated with JY-231